Curis (CRIS) Common Equity (2010 - 2026)
Curis' (CRIS) quarterly Common Equity came in at $12.7 million in Q1 2026, up 292.33% YoY from $3.2 million in Q1 2025, and up 132.64% on a QoQ basis from $5.5 million in Q4 2025.
Curis (CRIS) Common Equity (2010 - 2026) Analysis & Trends
Curis (CRIS) has 17 years of Common Equity data on file, last reported at $12.7 million in Q1 2026.
- Quarterly Common Equity rose 292.33% year-over-year to $12.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.7 million (up 292.33% YoY) and the FY2025 annual result came in at $5.5 million, up 191.06% from the prior year.
- Common Equity rose to $12.7 million in Q1 2026, from $5.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $76.0 million in Q1 2022 to a low of -$14.7 million in Q3 2025.
- A 5-year average of $19.4 million and a median of $12.7 million in 2026 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2025 — Common Equity tumbled 1915.27% — and 2026, when it surged 292.33%.
- Tracing CRIS's Common Equity over 5 years: stood at $46.6 million in 2022, then slumped by 57.75% to $19.7 million in 2023, then sank by 130.49% to -$6.0 million in 2024, then jumped by 191.06% to $5.5 million in 2025, then jumped by 132.64% to $12.7 million in 2026.
- The last three Common Equity figures came in at $12.7 million (Q1 2026), $5.5 million (Q4 2025), and -$14.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Curis | 3.44 Mn | -2.18 Mn | - | 4.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.71 Mn |
| Dec 31, 2025 | 5.46 Mn |
| Sep 30, 2025 | -14.69 Mn |
| Jun 30, 2025 | -13.99 Mn |
| Mar 31, 2025 | -6.61 Mn |
| Dec 31, 2024 | -6.00 Mn |
| Sep 30, 2024 | -8.74 Mn |
| Jun 30, 2024 | -694,000.00 |
| Mar 31, 2024 | 9.46 Mn |
| Dec 31, 2023 | 19.67 Mn |
| Sep 30, 2023 | 29.59 Mn |
| Jun 30, 2023 | 26.23 Mn |
| Mar 31, 2023 | 36.59 Mn |
| Dec 31, 2022 | 46.55 Mn |
| Sep 30, 2022 | 55.75 Mn |
| Jun 30, 2022 | 62.05 Mn |
| Mar 31, 2022 | 75.97 Mn |
| Dec 31, 2021 | 90.71 Mn |
| Sep 30, 2021 | 102.91 Mn |
| Jun 30, 2021 | 112.47 Mn |